Skip to main content

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.

Publication ,  Journal Article
Belshe, RB; Gorse, GJ; Mulligan, MJ; Evans, TG; Keefer, MC; Excler, JL; Duliege, AM; Tartaglia, J; Cox, WI; McNamara, J; Hwang, KL; Bradney, A ...
Published in: AIDS
December 24, 1998

OBJECTIVE: To determine the ability of live attenuated canarypox virus expressing HIV antigens to induce CD8+ cytotoxic T-cell responses and to prime for neutralizing antibody responses to boosting with purified recombinant gp120 subunit vaccine. DESIGN: A prospective, double-blind, randomized, immunogenicity and safety study was conducted in healthy adults at low risk for acquiring HIV infection and who were seronegative for HIV. METHODS: CD8+ cytotoxic T-cells directed against Env or Gag expressing target cells were measured after live recombinant canarypox-HIV-1 vaccine priming (vaccine given at days 0, 7, 14 and 21). Neutralizing antibodies were measured after subunit boosting (vaccine given at days 28 and 84). RESULTS: CD8+ CTL were induced in 64% of volunteers by the live recombinant canarypox-HIV-1 vaccine. All volunteers who received two doses of subunit vaccine after live recombinant canarypox priming developed neutralizing antibodies directed against laboratory strains of HIV-1 and seven out of eight volunteers tested developed neutralizing antibodies to the primary isolate, BZ167, but to none of eight other primary isolates. Unprimed controls had low or absent neutralizing antibodies after two doses of subunit vaccine. CONCLUSIONS: The live canarypox vector was safe, stimulated cytotoxic T-cells and primed for a vigorous neutralizing antibody response upon boosting with subunit gp120 vaccine. This vaccine combination should be evaluated further for inducing protection against HIV infection.

Duke Scholars

Published In

AIDS

DOI

ISSN

0269-9370

Publication Date

December 24, 1998

Volume

12

Issue

18

Start / End Page

2407 / 2415

Location

England

Related Subject Headings

  • Virology
  • Vaccines, Synthetic
  • T-Lymphocytes, Cytotoxic
  • Prospective Studies
  • Peptide Fragments
  • Neutralization Tests
  • Middle Aged
  • Immunization Schedule
  • Humans
  • HIV-1
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Belshe, R. B., Gorse, G. J., Mulligan, M. J., Evans, T. G., Keefer, M. C., Excler, J. L., … Weinhold, K. J. (1998). Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS, 12(18), 2407–2415. https://doi.org/10.1097/00002030-199818000-00009
Belshe, R. B., G. J. Gorse, M. J. Mulligan, T. G. Evans, M. C. Keefer, J. L. Excler, A. M. Duliege, et al. “Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.AIDS 12, no. 18 (December 24, 1998): 2407–15. https://doi.org/10.1097/00002030-199818000-00009.
Belshe, R. B., et al. “Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.AIDS, vol. 12, no. 18, Dec. 1998, pp. 2407–15. Pubmed, doi:10.1097/00002030-199818000-00009.
Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, Hwang KL, Bradney A, Montefiori D, Weinhold KJ. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS. 1998 Dec 24;12(18):2407–2415.

Published In

AIDS

DOI

ISSN

0269-9370

Publication Date

December 24, 1998

Volume

12

Issue

18

Start / End Page

2407 / 2415

Location

England

Related Subject Headings

  • Virology
  • Vaccines, Synthetic
  • T-Lymphocytes, Cytotoxic
  • Prospective Studies
  • Peptide Fragments
  • Neutralization Tests
  • Middle Aged
  • Immunization Schedule
  • Humans
  • HIV-1